Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives $55.29 Average Target Price from Brokerages

Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) have been given a consensus rating of “Moderate Buy” by the nine ratings firms that are currently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $55.2857.

A number of analysts have commented on KNSA shares. Zacks Research upgraded Kiniksa Pharmaceuticals International from a “strong sell” rating to a “hold” rating in a research report on Wednesday, February 25th. Wedbush boosted their price objective on Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the company an “outperform” rating in a research note on Wednesday, February 25th. Canaccord Genuity Group started coverage on shares of Kiniksa Pharmaceuticals International in a report on Thursday, February 19th. They issued a “buy” rating and a $62.00 target price for the company. Wall Street Zen downgraded shares of Kiniksa Pharmaceuticals International from a “buy” rating to a “hold” rating in a report on Saturday, March 14th. Finally, Wells Fargo & Company raised their price objective on shares of Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th.

Kiniksa Pharmaceuticals International Stock Performance

KNSA opened at $48.82 on Friday. Kiniksa Pharmaceuticals International has a 1-year low of $18.25 and a 1-year high of $49.33. The company has a market capitalization of $3.74 billion, a PE ratio of 65.97 and a beta of 0.06. The firm’s 50 day simple moving average is $45.53 and its two-hundred day simple moving average is $41.94.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings data on Tuesday, February 24th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.12). The business had revenue of $202.13 million for the quarter, compared to the consensus estimate of $200.86 million. Kiniksa Pharmaceuticals International had a net margin of 8.71% and a return on equity of 11.48%. The company’s revenue was up 65.0% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.12) EPS. Equities analysts forecast that Kiniksa Pharmaceuticals International will post -0.55 earnings per share for the current fiscal year.

Insider Transactions at Kiniksa Pharmaceuticals International

In related news, Director Barry D. Quart sold 2,690 shares of the stock in a transaction dated Thursday, February 12th. The stock was sold at an average price of $45.00, for a total transaction of $121,050.00. Following the completion of the sale, the director owned 12,546 shares in the company, valued at approximately $564,570. This trade represents a 17.66% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Mark Ragosa sold 17,845 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $43.28, for a total value of $772,331.60. Following the sale, the chief financial officer directly owned 12,086 shares in the company, valued at $523,082.08. This trade represents a 59.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 48,605 shares of company stock worth $2,122,646. Insiders own 53.48% of the company’s stock.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

A number of institutional investors have recently added to or reduced their stakes in the stock. EverSource Wealth Advisors LLC lifted its holdings in shares of Kiniksa Pharmaceuticals International by 140.4% in the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock worth $25,000 after buying an additional 532 shares in the last quarter. Osaic Holdings Inc. bought a new stake in Kiniksa Pharmaceuticals International in the 2nd quarter valued at $31,000. USA Financial Formulas purchased a new stake in Kiniksa Pharmaceuticals International in the 3rd quarter worth $32,000. Smartleaf Asset Management LLC purchased a new stake in Kiniksa Pharmaceuticals International in the 4th quarter worth $36,000. Finally, Nano Cap New Millennium Growth Fund L P bought a new position in shares of Kiniksa Pharmaceuticals International during the 4th quarter valued at about $41,000. 53.95% of the stock is owned by hedge funds and other institutional investors.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.